Headache, Migraine
Conditions
Keywords
migraine, headache
Brief summary
Numerous treatments have been recommended for the prevention of migraine. The purpose of this randomized double-blind placebo controlled trial was to assess the efficacy of MIGRAINEGUARD ™ supplement by Herbacure Natural containing a combination of COQ10 , magnesium, riboflavin ,feverfew , Skullcap and black pepper as prophylactic treatment for migraine.
Detailed description
Our team will assess MIGRAINEGUARD ™ , a migraine prevention supplement marketed Herbacure Natural for individual suffering from multiple migraine attacks in one month . The purpose of this 7-months , randomized, double-blind, placebo controlled study is to evaluate the efficacy and safety of MIGRAINEGUARD ™ produced by Herbacure Natural , A Canadian company based in Vancouver , BC , in reducing migraine headache severity and frequency of attacks compared to placebo when used every day, as a preventative solution for migraine and to assess and monitor the safety of its usage for adverse effects. The primary end-point is the severity and the frequency reduction of migraine attacks. The secondary end-points will be the existence of adverse reaction.
Interventions
DIETARY_SUPPLEMENTMigraineguard
2 Capsules per day for 7 Months
Sponsors
Herbacure Natural
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
DOUBLE (Subject, Caregiver)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
Yes
Inclusion criteria
* Adult aged 18 to 65 years Female and Male * Based on IHS criteria ,are diagnosed with migraine (criteria of the International Classification of Headaches Disorders) * Individuals with minimum of 3 severe to extreme migraine attacks during the last 3 months . * Generally in good health
Exclusion criteria
* Individuals taking any preventive treatment for migraine * Excessive usage of painkillers * Cancer & Head injury and trauma * Any medical condition that may impact the validity of collected information * Previous usage of Botox within 6 months of study * Last week usage of triptans
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of patient experiencing migraine attack reduction by at least 50 percent in one month . | 7 months | Number of patient experiencing migraine attack reduction by at least 50 percent in one month . Migraineurs with 50 percent migraine attack decrease are considered Responders to supplement. |
| Severity of migraine headache reduction after & Months | 7 Months | Reduction of Migraine severity After 7 months of supplementation |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Adverse Reactions | 7 months | Report of any adverse reaction due to supplementation during the study |
Countries
Canada
Outcome results
None listed